SARS-CoV-2: immunity, challenges with current vaccines, and a novel perspective on mucosal vaccines
The global rollout of COVID-19 vaccines has played a critical role in reducing pandemic
spread, disease severity, hospitalizations, and deaths. However, the first-generation …
spread, disease severity, hospitalizations, and deaths. However, the first-generation …
Advances and future perspectives of intranasal drug delivery: A scientometric review
D Xu, XJ Song, X Chen, JW Wang, YL Cui - Journal of Controlled Release, 2024 - Elsevier
Intranasal drug delivery is as a noninvasive and efficient approach extensively utilized for
treating the local, central nervous system, and systemic diseases. Despite numerous …
treating the local, central nervous system, and systemic diseases. Despite numerous …
Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection
Intranasal vaccination represents a promising approach for preventing disease caused by
respiratory pathogens by eliciting a mucosal immune response in the respiratory tract that …
respiratory pathogens by eliciting a mucosal immune response in the respiratory tract that …
Intranasal COVID-19 vaccine induces respiratory memory T cells and protects K18-hACE mice against SARS-CoV-2 infection
BK Diallo, C Ní Chasaide, TY Wong, P Schmitt, KS Lee… - npj Vaccines, 2023 - nature.com
Current COVID-19 vaccines prevent severe disease, but do not induce mucosal immunity or
prevent infection with SARS-CoV-2, especially with recent variants. Furthermore, serum …
prevent infection with SARS-CoV-2, especially with recent variants. Furthermore, serum …
An intranasal vaccine comprising SARS-CoV-2 spike receptor-binding domain protein entrapped in mannose-conjugated chitosan nanoparticle provides protection in …
K Tabynov, M Solomadin, N Turebekov, M Babayeva… - Scientific Reports, 2023 - nature.com
We developed a novel intranasal SARS-CoV-2 subunit vaccine called NARUVAX-C19/Nano
based on the spike protein receptor-binding domain (RBD) entrapped in mannose …
based on the spike protein receptor-binding domain (RBD) entrapped in mannose …
SARS-CoV-2 Delta variant induces enhanced pathology and inflammatory responses in K18-hACE2 mice
The COVID-19 pandemic has been fueled by SARS-CoV-2 novel variants of concern (VOC)
that have increased transmissibility, receptor binding affinity, and other properties that …
that have increased transmissibility, receptor binding affinity, and other properties that …
Intranasal immunization with liposome-displayed receptor-binding domain induces mucosal immunity and protection against SARS-CoV-2
The global pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), has led to efforts in develo** effective vaccine approaches. Currently, approved …
CoV-2), has led to efforts in develo** effective vaccine approaches. Currently, approved …
Physicochemical characterization of biological and synthetic forms of two lipid A-based TLR4 agonists
G Hu, DJ Varisco, S Das, CR Middaugh, F Gardner… - Heliyon, 2023 - cell.com
Toll-like receptor (TLR) agonists are recognized as potential immune-enhancing adjuvants
and are included in several licensed vaccines. Monophosphoryl lipid A (MPL® …
and are included in several licensed vaccines. Monophosphoryl lipid A (MPL® …
A Dual‐Adjuvanted Parenteral‐Intranasal Subunit Nanovaccine generates Robust Systemic and Mucosal Immunity Against SARS‐CoV‐2 in Mice
Existing parenteral SARS‐CoV‐2 vaccines produce only limited mucosal responses,
essential for reducing transmission and achieving sterilizing immunity. Appropriately …
essential for reducing transmission and achieving sterilizing immunity. Appropriately …
RBD-VLP vaccines adjuvanted with Alum or SWE protect K18-hACE2 mice against SARS-CoV-2 VOC challenge
The ongoing COVID-19 pandemic has contributed largely to the global vaccine disparity.
Development of protein subunit vaccines can help alleviate shortages of COVID-19 vaccines …
Development of protein subunit vaccines can help alleviate shortages of COVID-19 vaccines …